Questcor Pharmaceuticals (QCOR) makes drugs that help patients with serious medical problems. Most of their sales are from Acthar an injectable drug used in 19 indications. Most of the revenues are derived from patients with adults with multiple sclerosis and children under 2 who suffer from infantile spasms. The drug is also approved for the treatment of lupus erythematosus.
The company’s other leading drug is Doral which is approved for treating insomnia. Earnings are up over 100% so far this year and the stock was upgraded to an A by Portfolio Grader back in September.
QCOR is a strong buy at the current price.